Celldex Other Stockholder Equity vs Net Debt Analysis
CLDX Stock | USD 38.21 1.73 4.33% |
Celldex Therapeutics financial indicator trend analysis is way more than just evaluating Celldex Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Celldex Therapeutics is a good investment. Please check the relationship between Celldex Therapeutics Other Stockholder Equity and its Net Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.
Other Stockholder Equity vs Net Debt
Other Stockholder Equity vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Celldex Therapeutics Other Stockholder Equity account and Net Debt. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Celldex Therapeutics' Other Stockholder Equity and Net Debt is -0.05. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Net Debt in the same time period over historical financial statements of Celldex Therapeutics, assuming nothing else is changed. The correlation between historical values of Celldex Therapeutics' Other Stockholder Equity and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Celldex Therapeutics are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Other Stockholder Equity i.e., Celldex Therapeutics' Other Stockholder Equity and Net Debt go up and down completely randomly.
Correlation Coefficient | -0.05 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Other Stockholder Equity
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from Celldex Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Celldex Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.At this time, Celldex Therapeutics' Tax Provision is fairly stable compared to the past year. Enterprise Value is likely to rise to about 1.8 B in 2024, whereas Selling General Administrative is likely to drop slightly above 29.4 M in 2024.
2023 | 2024 (projected) | Extraordinary Items | 17.2M | 15.3M | Reconciled Depreciation | 2.9M | 3.1M |
Celldex Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Celldex Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Celldex Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 122.9M | 235.8M | 444.7M | 352.7M | 465.6M | 488.9M | |
Other Current Liab | 2.0M | 3.4M | 1.6M | 13.8M | 26.0M | 27.3M | |
Total Current Liabilities | 11.6M | 14.2M | 16.5M | 18.6M | 31.1M | 32.7M | |
Total Stockholder Equity | 94.0M | 209.4M | 419.5M | 326.2M | 429.2M | 450.6M | |
Property Plant And Equipment Net | 4.0M | 3.8M | 3.6M | 3.7M | 6.6M | 5.7M | |
Net Debt | (7.6M) | (40.4M) | (36.1M) | (25.4M) | (32.3M) | (33.9M) | |
Retained Earnings | (1.0B) | (1.1B) | (1.1B) | (1.3B) | (1.4B) | (1.3B) | |
Cash | 11.2M | 43.8M | 39.1M | 29.4M | 34.8M | 31.5M | |
Non Current Assets Total | 56.2M | 38.0M | 33.8M | 35.0M | 33.9M | 31.0M | |
Cash And Short Term Investments | 64.4M | 194.4M | 408.3M | 305.0M | 421.7M | 442.8M | |
Common Stock Shares Outstanding | 14.5M | 29.6M | 42.9M | 46.9M | 48.4M | 50.9M | |
Liabilities And Stockholders Equity | 122.9M | 235.8M | 444.7M | 352.7M | 465.6M | 488.9M | |
Non Current Liabilities Total | 17.3M | 12.3M | 8.7M | 7.9M | 5.3M | 5.1M | |
Other Current Assets | 2.3M | 3.4M | 2.6M | 12.7M | 5.5M | 2.9M | |
Other Stockholder Equity | 1.1B | 1.3B | 1.6B | 1.6B | 1.8B | 1.9B | |
Total Liab | 28.9M | 26.5M | 25.2M | 26.5M | 36.5M | 25.7M | |
Property Plant And Equipment Gross | 7.5M | 7.3M | 27.6M | 29.4M | 29.0M | 30.5M | |
Total Current Assets | 66.7M | 197.8M | 410.8M | 317.7M | 431.7M | 453.3M | |
Accumulated Other Comprehensive Income | 2.6M | 2.6M | 1.9M | 1.3M | 3.3M | 3.5M | |
Net Receivables | 1.0M | 1.8M | 172K | 347K | 4.5M | 4.8M | |
Inventory | (1.0M) | (1.8M) | (172K) | (347K) | 1.0 | 0.95 | |
Accounts Payable | 1.2M | 1.0M | 1.2M | 3.3M | 3.5M | 3.7M | |
Short Long Term Debt Total | 3.7M | 3.5M | 3.0M | 4.0M | 2.5M | 4.6M | |
Short Term Debt | 1.9M | 1.3M | 1.7M | 1.4M | 1.6M | 2.6M | |
Common Stock Total Equity | 12K | 17K | 40K | 47K | 54.1K | 65.1K | |
Common Stock | 12K | 17K | 40K | 47K | 56K | 64.5K | |
Intangible Assets | 52.2M | 34.2M | 30.3M | 31.3M | 27.2M | 34.2M | |
Current Deferred Revenue | 2.5M | 6.5M | 8.5M | 12M | 10.8M | 10.3M | |
Other Liab | 15.6M | 10.1M | 7.4M | 5.3M | 6.1M | 5.8M | |
Property Plant Equipment | 4.0M | 7.3M | 6.5M | 7.7M | 7.0M | 7.2M | |
Short Term Investments | 53.2M | 150.6M | 369.1M | 275.5M | 386.9M | 406.2M | |
Net Tangible Assets | 45.3M | 178.7M | 392.3M | 299.0M | 343.9M | 361.1M | |
Retained Earnings Total Equity | (962.4M) | (1.0B) | (1.1B) | (1.1B) | (1.0B) | (1.1B) | |
Capital Surpluse | 1.1B | 1.1B | 1.3B | 1.6B | 1.8B | 1.0B | |
Non Current Liabilities Other | 17.3M | 10.1M | 7.4M | 5.3M | 4.4M | 4.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Celldex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Celldex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Celldex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Celldex Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.Note that the Celldex Therapeutics information on this page should be used as a complementary analysis to other Celldex Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Celldex Stock analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Celldex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celldex Therapeutics. If investors know Celldex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Celldex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.86) | Revenue Per Share 0.118 | Quarterly Revenue Growth (0.84) | Return On Assets (0.16) | Return On Equity (0.25) |
The market value of Celldex Therapeutics is measured differently than its book value, which is the value of Celldex that is recorded on the company's balance sheet. Investors also form their own opinion of Celldex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Celldex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Celldex Therapeutics' market value can be influenced by many factors that don't directly affect Celldex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Celldex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Celldex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Celldex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.